Review



fty720  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Merck & Co fty720
    Fty720, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/compound+fty720/pm41903139-250-10-11
    Average 86 stars, based on 1 article reviews
    fty720 - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Transplantation Assay:

    Article Title: PGE 2 limits effector expansion of tumour-infiltrating stem-like CD8 + T cells.
    Article Snippet: CD4+ and CD8+ T cell depletion in vivo To deplete CD4+ and CD8+ T cells, mice received intraperitoneal (i.p.) injections of 100 μl anti-mouse CD4 (100 μg per mouse, GK1.5, BioXCell) or anti-mouse CD8β (100 μg per mouse, 53-5.8, BioXCell) antibodies every 5 days, beginning on day 1 following tumour cell inoculation. .. FTY720 treatment was performed by injecting mice i.p. with 100 μl of FTY720 (20 μg per mouse, Merck) on day 1 or day 6 after tumour cell transplantation. ..

    Article Title: PGE 2 limits effector expansion of tumour-infiltrating stem-like CD8 + T cells
    Article Snippet: To deplete CD4 + and CD8 + T cells, mice received intraperitoneal (i.p.) injections of 100 μl anti-mouse CD4 (100 μg per mouse, GK1.5, BioXCell) or anti-mouse CD8β (100 μg per mouse, 53-5.8, BioXCell) antibodies every 5 days, beginning on day 1 following tumour cell inoculation. .. FTY720 treatment was performed by injecting mice i.p. with 100 μl of FTY720 (20 μg per mouse, Merck) on day 1 or day 6 after tumour cell transplantation. ..

    Saline:

    Article Title: Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regulatory T cell responses through averting ceramide-mediated pathways.
    Article Snippet: .. A further two groups of animals (6–7 animals each) were fed a WD for 21 days and treated with the ceramide synthase inhibitor FTY720 (SML0700-5MG; Merck, Gillingham, UK) [30] via 3 intraperitoneal injections (i.p.) (1 mg/kg) given D. Camacho-Muñoz et al. Biochemical Pharmacology 204 (2022) 115211 at days 11, 16 and 18, or saline (vehicle control), as previously described [31,32]. ..

    Control:

    Article Title: Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regulatory T cell responses through averting ceramide-mediated pathways.
    Article Snippet: .. A further two groups of animals (6–7 animals each) were fed a WD for 21 days and treated with the ceramide synthase inhibitor FTY720 (SML0700-5MG; Merck, Gillingham, UK) [30] via 3 intraperitoneal injections (i.p.) (1 mg/kg) given D. Camacho-Muñoz et al. Biochemical Pharmacology 204 (2022) 115211 at days 11, 16 and 18, or saline (vehicle control), as previously described [31,32]. ..



    Similar Products

    fty720  (MedChemExpress)
    97
    MedChemExpress fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Fty720, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/Fingolimod+hydrochloride/pmc12996997-359-0-11
    Average 97 stars, based on 1 article reviews
    fty720 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    fty720 treatment  (TargetMol)
    94
    TargetMol fty720 treatment
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Fty720 Treatment, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/Fingolimod/pm41904143-334-2-6
    Average 94 stars, based on 1 article reviews
    fty720 treatment - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    modulator fty720 targets sphingosine 1 phosphate receptors  (Brinkmann Instruments)
    86
    Brinkmann Instruments modulator fty720 targets sphingosine 1 phosphate receptors
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Modulator Fty720 Targets Sphingosine 1 Phosphate Receptors, supplied by Brinkmann Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/1+fty720+modulator+phosphate+receptors+sphingosine+targets/pm42268470-257-35-6
    Average 86 stars, based on 1 article reviews
    modulator fty720 targets sphingosine 1 phosphate receptors - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    immunosuppressive drug fty720  (Novartis)
    86
    Novartis immunosuppressive drug fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Immunosuppressive Drug Fty720, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/fty720/pm42041530-19-17-22
    Average 86 stars, based on 1 article reviews
    immunosuppressive drug fty720 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    sev fty720  (MedChemExpress)
    97
    MedChemExpress sev fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Sev Fty720, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/Fingolimod/pm41981595-84-70-75
    Average 97 stars, based on 1 article reviews
    sev fty720 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    fty720  (Brinkmann Instruments)
    86
    Brinkmann Instruments fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Fty720, supplied by Brinkmann Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/1+receptor+s1p/pm41941276-93-13-17
    Average 86 stars, based on 1 article reviews
    fty720 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    fty720  (TargetMol)
    94
    TargetMol fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Fty720, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/Fingolimod/pm41904143-334-5-6
    Average 94 stars, based on 1 article reviews
    fty720 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    fty720  (Merck & Co)
    86
    Merck & Co fty720
    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with <t>FTY720.</t> (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
    Fty720, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fty720/compound+fty720/pm41903139-250-10-11
    Average 86 stars, based on 1 article reviews
    fty720 - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with FTY720. (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

    Journal: Bioactive Materials

    Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

    doi: 10.1016/j.bioactmat.2026.03.012

    Figure Lengend Snippet: TRANS enhances tumoral T cell abundance and synergizes with immune checkpoint inhib itors. (A) UMAP visualization of lymphocytes in the TME following PBS or TRANS treatment. (B) UMAP visualization of lymphocyte clusters. (C) Proportional distribution of lymphocyte clusters. (D) Expression of cluster-specific marker genes. (E) Top 10 maker genes in CD8 + effector T cells (Teff). (F) Volcano plot of differentially expressed genes in CD8 + Teff between TRANS and PBS. (G) Dot plot showing upregulated pathways in IFN-γ + T cells (TRANS vs PBS), with dot size reflecting KEGG enrichment intensity. (H) Dot plot of ligand-receptor interactions between myeloid cells and T cells (TRANS vs PBS). Ligands (blue) and receptors (red) are labeled. (I) Experimental design of tumor therapy by TRANS combination with FTY720. (J) Tumor growth curve in mice treated with PBS, TRANS, and FTY720+TRANS; n = 5. (K – M) Tumor-infiltrating CD4 + and CD8 + T cells (K), Granzyme + CD8 + T or IFN-γ + CD8 + T cells counts (L), and Exhausted T cells (M) in TME; n = 5. (N) Scheme of tumor therapy by TRANS combined with immune checkpoint inhibitors (ICI). (O and P) Individual tumor changes (O) and Survival rate (Q) of tumor-bearing mice with different treatments; n = 5. (Q and R) Ex vivo IFN-γ expression (Q) and Quantification (R) in splenic CD8 + T cells with PMA/ionomycin stimulation; n = 3. (S) IFN-γ secretion by splenic T cells following αCD3/αCD28 stimulation; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

    Article Snippet: FTY720, AMG 487, TAK-779, D-Mannitol, and hydroxypropyl-β-cyclodextrin (HP-β-CD) were provided by MedChemExpress (USA).

    Techniques: Inhibition, Expressing, Marker, Labeling, Ex Vivo